Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.
about
Role of erlotinib in the treatment of non-small cell lung cancer: clinical outcomes in wild-type epidermal growth factor receptor patientsTargeted therapy for orbital and periocular basal cell carcinoma and squamous cell carcinomaEpidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC)The Lake Wobegon effect: are all cancer patients above average?Survival outcomes in patients with advanced non-small cell lung cancer treated with erlotinib: expanded access programme data from Belgium (the TRUST study).Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: a case report.Erlotinib in patients with advanced non-small-cell lung cancer: impact of dose reductions and a novel surrogate marker.Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer.Bortezomib therapy-related lung disease in Japanese patients with multiple myeloma: incidence, mortality and clinical characterizationFirst-line antiretroviral therapy and dyslipidemia in people living with HIV-1 in Cameroon: a cross-sectional study.Treatment of Non-Small-Cell Lung Cancer with Erlotinib following Gefitinib-Induced Hepatotoxicity: Review of 8 Clinical Cases.Treatment of advanced non small cell lung cancer.EGFR tyrosine kinase targeted compounds: in vitro antitumor activity and molecular modeling studies of new benzothiazole and pyrimido[2,1-b]benzothiazole derivativesThe Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study.First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors.Maintenance erlotinib improves clinical outcomes of unresectable advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials.Epidermal growth factor receptor tyrosine kinase inhibitors with conventional chemotherapy for the treatment of non-small cell lung cancer.Evaluation of Three Small Molecular Drugs for Targeted Therapy to Treat Nonsmall Cell Lung Cancer.A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatmentsReadMax-a novel reading and scoring approach for EGFR gene copy number to predict therapeutic benefit of erlotinib treatment in EGFR wild-type non-small-cell lung cancer.Dermatologic events from EGFR inhibitors: the issue of the missing patient voice.Role of erlotinib in the targeted treatment of non-small-cell lung cancer in Chinese patients.Factors associated with early progression of non-small-cell lung cancer treated by epidermal growth factor receptor tyrosine-kinase inhibitors.Erlotinib-induced complete response in a patient with epidermal growth factor receptor wild-type lung adenocarcinoma after chemotherapy failure: a case report.Reviewing the safety of erlotinib in non-small cell lung cancer.Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib.A benefit-risk assessment of erlotinib in non-small-cell lung cancer and pancreatic cancer.Angiogenesis-related molecular targets in esophageal cancer.Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer.Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review.Erlotinib in the first-line treatment of non-small-cell lung cancer.Anterior Uveitis Caused by Ocular Side Effects of Afatinib: A Case Report.The Utility of Exercise Testing in Patients with Lung Cancer.Venous Thromboembolism in Patients Diagnosed With Lung Cancer.Structure-based drug design and biological evaluation of 2-acetamidobenzothiazole derivative as EGFR kinase inhibitor.Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.Moving towards molecular-guided treatments: erlotinib and clinical outcomes in non-small-cell lung cancer patients.Efficacy of erlotinib in previously treated patients with advanced non-small cell lung cancer: analysis of the Chinese subpopulation in the TRUST study.Acute myocardial infarction following erlotinib treatment for NSCLC: A case report.
P2860
Q26866485-D8724D11-4487-4A39-9477-9B1FCC487C7DQ26995961-48CD2045-C1E6-47AD-A3BE-8AC6B8D1E824Q28284519-44832815-B770-4136-BA02-35DD5C083E91Q28303620-8CFC3F9D-621E-4409-800C-6CA7FF36B2B0Q30683030-C73A02E1-409D-4C5C-9988-38C29AE081D0Q33739969-ABCA0029-5B4C-4A3D-9723-50A8AD167A0FQ33822521-E3BE4D53-81E3-4852-89E3-361AEF8B7CDBQ34031229-CF157743-A5BE-4C19-B073-D6BFD5A5C8C2Q35051496-26B4BCD1-12D6-4FAC-8316-F9508FEB5D6EQ35397077-E2B4F4F2-5CAA-4EEC-A899-A3F9BE39D045Q35623614-855A68D9-799A-4A59-B491-5621E63CD992Q35667817-80A5F613-B93E-41D1-856C-9E6CF08996F4Q35729147-BDC12382-8522-48E1-9015-54511FDC79D3Q35850480-A021A67F-4C01-421E-8B08-4469E1FF6450Q36283596-890E400E-3CF3-4B41-BAC2-ADC93FBA4769Q36385229-3C48FEAA-6A84-455D-BB39-43A0F5170541Q36402837-3CEAB3E3-FF11-4519-851E-96E880448AAFQ36705603-CCBD2955-C2B0-4A4F-96E1-86F0277A43B6Q36740744-C09D6E5C-A3A3-46CA-A9AF-7A9F3BF515DBQ37082514-C5FC8C25-DC53-4700-A0AF-6EC86BB582BEQ37541523-DE8EC577-C6E3-4958-B3D8-389C9A922009Q37591935-CB8654BE-8E9C-4474-A1DE-C2514DA0099AQ37595242-5428366C-1326-4586-BD41-6A038A08AE31Q37689074-996847AC-BE2E-41FC-BF3D-0E9584A4131FQ37817466-6B826B40-6B9A-4DCF-B853-C401B629E5F5Q37823422-C23A2EC5-03AF-468D-B2E4-E3C51E8F9C82Q37844529-E0712C47-5948-4C7F-8EC1-CD7B3AD49DAEQ37858534-1DA76915-A713-442E-B8A1-CAED7A2A1772Q37909352-E7B62178-0075-47EB-9DB4-1DA6B6A07D66Q37945643-85E0DDC6-7247-49DD-843F-7979DDC04B36Q38059784-6BA072E3-7E7E-4734-8A05-1CEB351290ECQ38101604-8B42601D-E75C-4A1E-96D5-03817A9DA51CQ38694622-52914980-5D3F-467D-B738-34B8EA814EA2Q38828542-D659AF15-7587-420A-8017-920B9D005345Q38944457-5F5DB555-3FEC-4E58-B534-6148A9CAE514Q39018134-9AF32E8A-3677-4918-8238-DD1184501982Q39388106-14524094-8AB0-4B70-A9A1-C026EEBF8FBCQ39455567-EECC6572-44A7-42EA-B59E-1D625A9C9852Q41099007-7721F137-2FB5-494A-A77A-C6C77E06FCAFQ41843998-122C1050-B7B2-4AF3-86DD-6C1DDD955193
P2860
Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Erlotinib in advanced non-smal ...... ncer Survival Treatment study.
@en
Erlotinib in advanced non-smal ...... ncer Survival Treatment study.
@nl
type
label
Erlotinib in advanced non-smal ...... ncer Survival Treatment study.
@en
Erlotinib in advanced non-smal ...... ncer Survival Treatment study.
@nl
prefLabel
Erlotinib in advanced non-smal ...... ncer Survival Treatment study.
@en
Erlotinib in advanced non-smal ...... ncer Survival Treatment study.
@nl
P2093
P50
P1476
Erlotinib in advanced non-smal ...... ncer Survival Treatment study.
@en
P2093
Danny Rischin
David Heigener
Martin Reck
Simon Allan
Zoltan Baliko
P304
P356
10.1097/JTO.0B013E3181F1C7B0
P577
2010-10-01T00:00:00Z